AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
Credit Suisse initiated coverage of AC Immune Ltd (NASDAQ: ACIU) with an Outperform rating and an $18 price target.
Alzheimer's Pure Play
Analyst Alethia Young noted that the company's lead product crenezumab is in a late-stage trial in partnership with Roche Holding Ltd. (ADR) (OTC: RHHBY). Along with crenezumab, the company is developing other assets, which provide it optionality with early Alzheimer's disease targets like Tau or AD vaccines, the firm said.
High Risk/High Reward Story
Credit Suisse views the story as high risk/reward in the near term, premised on three reasons. While noting that no AD asset is exactly the same and the designs are different too, the firm said it is uncertain of the failure of Eli Lilly and Co (NYSE: LLY) solanezumab would mean all other drugs fail.
The firm expects AC Immune and Biogen Inc (NASDAQ: BIIB) to go ahead with their studies, even if Eli Lilly's fail completely. Credit Suisse also indicated that AC Immune has other assets that could be used in combination or separately from crenezumab.
Credit Suisse believes the most important AC Immune specific catalyst is the publication of higher dose of crenezumab data.
- Since Roche controls the publication, the firm is uncertain when the publication will occur, although it surmises that it might occur by key AD meeting called CTAD scheduled for December 8–10, 2016.
- The firm also expects some early data on other programs later this year and early data on Tau vaccine partnered with Janssen in 2017. Tau Phase 2 trial is set to being in 2017, the firm noted.
Credit Suisse believes AC Immune could trade at $20 to $23 per share if data supports amyloid hypothesis but could drop down to $6-$9 if amyloid hypothesis is proved irrelevant.
At last check, the shares of the AC Immune were up 3.19 percent at $14.89.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email email@example.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for ACIU
|Oct 2016||Leerink Swann||Initiates Coverage On||Outperform|
|Oct 2016||Credit Suisse||Initiates Coverage On||Outperform|
|Oct 2016||Jefferies||Initiates Coverage On||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.